Megan Stinefelt, DNP | |
579 Baltimore Annapolis Blvd, Severna Park, MD 21146-3809 | |
(410) 975-5447 | |
Not Available |
Full Name | Megan Stinefelt |
---|---|
Gender | Female |
Speciality | Preventive Medicine - Obesity Medicine |
Location | 579 Baltimore Annapolis Blvd, Severna Park, Maryland |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1750921094 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083B0002X | Preventive Medicine - Obesity Medicine | R170745 (Maryland) | Primary |
Entity Name | Aps Corelife Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1780209866 PECOS PAC ID: 3971926122 Enrollment ID: O20200707002862 |
News Archive
Pay-for-performance (P4P) programs are payment models that reward workers for meeting certain performance measures for quality and efficiency. In the healthcare setting, P4P programs use a variety of methods to reward physicians financially for achieving targets, including fee differentials and bonuses.
Gloria E. Meredith, Ph.D., collaborated with D. James Surmeier, Ph.D. and other scientists at Northwestern University to study the drug, Isradipine, and its possible effects on Parkinson's disease.
The World Health Organization (WHO) is calling the new strain of H7H9 influenza virus "lethal" and The University of Kansas Hospital is preparing now for any potential cases.
The U.S. Supreme Court is to decide whether anti-drug laws should apply to the medicinal use of marijuana.
CardioVascular BioTherapeutics, Inc. today announced it has submitted an application to the U.S. FDA to obtain "fast track" designation for CVBT-141B, its biological therapy to treat ischemic diabetic wounds based on the active ingredient fibroblast growth factor-1 (FGF-1).
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Megan Stinefelt, DNP 1201 Latrobe Dr, Annapolis, MD 21409-5130 Ph: (240) 446-5860 | Megan Stinefelt, DNP 579 Baltimore Annapolis Blvd, Severna Park, MD 21146-3809 Ph: (410) 975-5447 |
News Archive
Pay-for-performance (P4P) programs are payment models that reward workers for meeting certain performance measures for quality and efficiency. In the healthcare setting, P4P programs use a variety of methods to reward physicians financially for achieving targets, including fee differentials and bonuses.
Gloria E. Meredith, Ph.D., collaborated with D. James Surmeier, Ph.D. and other scientists at Northwestern University to study the drug, Isradipine, and its possible effects on Parkinson's disease.
The World Health Organization (WHO) is calling the new strain of H7H9 influenza virus "lethal" and The University of Kansas Hospital is preparing now for any potential cases.
The U.S. Supreme Court is to decide whether anti-drug laws should apply to the medicinal use of marijuana.
CardioVascular BioTherapeutics, Inc. today announced it has submitted an application to the U.S. FDA to obtain "fast track" designation for CVBT-141B, its biological therapy to treat ischemic diabetic wounds based on the active ingredient fibroblast growth factor-1 (FGF-1).
› Verified 7 days ago